Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2019 /
Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer

27th Sep - 1st Oct 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.10.19
Views: 2563
Rating:

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Prof Sherene Loi speaks to ecancer at ESMO 2019 in Barcelona about how PARP inhibitors are currently being used to treat metastatic breast cancer.

Focusing on patients' quality of life, Prof Loi discusses which PARP inhibitors are currently approved in this setting, how they are currently being used, and with what results.

This programme has been supported by an unrestricted educational grant from Pfizer.

 

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation